aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Analysts

Key Points

• Consensus "Hold": Seven analysts cover aTyr Pharma with a consensus Hold rating (1 sell, 5 hold, 1 buy) and an average 12‑month price target of $25.67.
• Shares opened at $0.79 and were trading down about 4.6%, with a market cap of roughly $77.4 million and a 52‑week range of $0.64 to $7.29, reflecting continued low absolute valuation despite volatility.
• aTyr is a clinical‑stage biotech developing extracellular modulation therapies for rare diseases; it reported ($0.14) EPS last quarter (beating estimates) and analysts forecast about ($0.91) EPS for the year, while institutional investors own about 61.7% of the stock.

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) has been given a consensus recommendation of "Hold" by the seven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $25.6667.

Several analysts recently commented on ATYR shares. Jefferies Financial Group reissued a "buy" rating on shares of aTyr Pharma in a research note on Friday, March 6th. Wall Street Zen raised aTyr Pharma from a "sell" rating to a "hold" rating in a report on Sunday, March 15th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of aTyr Pharma in a research report on Monday, December 29th.

aTyr Pharma Trading Down 4.6%

Shares of aTyr Pharma stock opened at $0.79 on Wednesday. aTyr Pharma has a 52 week low of $0.64 and a 52 week high of $7.29. The stock has a market cap of $77.42 million, a PE ratio of -1.00 and a beta of 0.55. The company's 50-day moving average price is $0.87 and its two-hundred day moving average price is $1.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. On average, equities analysts predict that aTyr Pharma will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On aTyr Pharma

Several hedge funds have recently modified their holdings of the stock. Profund Advisors LLC acquired a new position in shares of aTyr Pharma in the 3rd quarter valued at $27,000. California State Teachers Retirement System acquired a new stake in aTyr Pharma during the 2nd quarter worth about $28,000. ADAR1 Capital Management LLC lifted its stake in aTyr Pharma by 35.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company's stock valued at $40,000 after buying an additional 13,385 shares in the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in aTyr Pharma during the fourth quarter valued at about $41,000. Finally, Ameritas Investment Partners Inc. acquired a new position in shares of aTyr Pharma in the second quarter worth about $45,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company's research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.